Jonathan Bates
Internal Medicine · Emporia, KSNPI 1336709237
Payments from drug & device makers
Across 67 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$145
- AstraZeneca$105
- Boehringer Ingelheim$100
- AbbVie$95
- Boston Scientific$94
- Novo Nordisk$86
- plus $621 from 18 others
What the payments were for
- Food & beverage$1,246100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $145 |
| AstraZeneca | 7 | $105 |
| Boehringer Ingelheim | 6 | $100 |
| AbbVie | 6 | $95 |
| Boston Scientific | 1 | $94 |
| Novo Nordisk | 4 | $86 |
| Insulet Corporation | 3 | $73 |
| Bayer | 4 | $67 |
| Lilly USA, LLC | 4 | $64 |
| Dexcom, Inc. | 4 | $59 |
| Cequr Corporation | 1 | $58 |
| Amgen | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Viiv Healthcare Company | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $20 |
| Seqirus USA Inc | 1 | $18 |
| Merck | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| GSK | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,246 in reported general payments places this provider in the 75th percentile of 705 internal medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 62 | $46,185 |
| EliquisApixaban | 27 | $16,096 |
| OzempicSemaglutide | 13 | $12,352 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $9,817 |
| MyrbetriqMirabegron | 14 | $8,635 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,204 |
| XareltoRivaroxaban | 14 | $7,685 |
| Lidocaine | 14 | $2,104 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,576 |
| Gabapentin | 122 | $1,526 |
| Tizanidine Hcl | 27 | $1,210 |
| Atorvastatin Calcium | 128 | $687 |
| Duloxetine Hcl | 52 | $654 |
| Levothyroxine Sodium | 87 | $619 |
| Pantoprazole Sodium | 78 | $541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $100 | $46,18562 claims |
| PfizerEliquis | $145 | $16,09627 claims |
| Novo NordiskOzempic | $86 | $12,35213 claims |
| GSKTrelegy Ellipta | $14 | $8,20413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Emporia
- Charisse SymmondsEmporia$14K
- Martin KankamLeavenworth$63.4M
- Mark HamblinKansas City$5.2M
- Katherine WillinghamTopeka$4.8M
- Raed Al RajabiWestwood$4.5M
- Leslie SpikesKansas City$4.5M
- Michael CoxTopeka$3.4M
- James RuhlmannHutchinson$2.8M
- Scott TeeterTopeka$1.2M
- Shadi HamdehKansas City$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.